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Host-directed therapies against HIV-1 are thought to be
critical for long term containment of the HIV-1 pandemic
but remain elusive. Because HIV-1 infects and manipu-
lates important effectors of both the innate and adaptive
immune system, identifying modulations of the host cell
systems in humans during HIV-1 infection may be crucial
for the development of immune based therapies. Here, we
quantified the changes of the proteome in human CD4 T
cells upon HIV-1 infection, both in vitro and in vivo. A
SWATH-MS approach was used to measure the proteome
of human primary CD4 T cells infected with HIV-1 in vitro
as well as CD4 T cells from HIV-1-infected patients with
paired samples on and off antiretroviral treatment. In the
in vitro experiment, the proteome of CD4 T cells was
quantified over a time course following HIV-1 infection.
1,725 host cell proteins and 4 HIV-1 proteins were quan-
tified, with 145 proteins changing significantly during the
time course. Changes in the proteome peaked 24 h after
infection, concomitantly with significant HIV-1 protein
production. In the in vivo branch of the study, CD4 T cells
from viremic patients and those with no detectable viral
load after treatment were sorted, and the proteomes were
quantified. We consistently detected 895 proteins, 172 of
which were considered to be significantly different be-
tween the viremic patients and patients undergoing suc-
cessful treatment. The proteome of the in vitro-infected
CD4 T cells was modulated on multiple functional levels,
including TLR-4 signaling and the type 1 interferon sig-
naling pathway. Perturbations in the type 1 interferon
signaling pathway were recapitulated in CD4 T cells
from patients. The study shows that proteome maps
generated by SWATH-MS indicate a range of function-
ally significant changes in the proteome of HIV-infected
human CD4 T cells. Exploring these perturbations in
more detail may help identify new targets for immune
based interventions. Molecular & Cellular Proteomics
16: 10.1074/mcp.M116.065235, S108–S123, 2017.
Therapeutic approaches against HIV-1 are mired in dichot-
omy. On the one hand, drugs targeting the virus are turning
HIV infection successfully into a therapeutically manageable
chronic disease, blocking transmission and increasing sur-
vival dramatically (1). On the other hand, host-targeted ap-
proaches such as vaccines or attempts to repair or boost the
immune system failed without exception (2, 3). However, it is
generally assumed that vaccines and sterilizing treatment are
prerequisites to eradicate HIV-1, because lifelong treatment is
difficult to implement, costly, and has side effects (4).
Current antiretroviral therapy stops viral replication but can-
not kill latently infected cells. Therefore, other approaches are
needed that can reverse HIV-1 latency or increase innate or
adaptive immune responses to kill latently infected cells. Be-
cause the virus requires host cells for replication and survival,
it needs to interact and modify the host environment to its
advantage. Although these complex interactions have been
extensively studied on a transcriptional level (5, 6), the knowl-
edge about the changes on the protein level are sparse (7, 8).
Therefore, more knowledge on the effects of HIV-1 on host
proteome networks in human cells infected by the virus is
needed to better understand virus-host interactions. It has
been estimated that genetic determinants of the virus are
responsible for 30–50% of the variability of the viral set point,
a surrogate marker for disease progression and compared
with 20% of the host genome (9). Thus, exploring host net-
works in clinically well characterized human individuals in-
fected with HIV-1 is crucial for the advancement of host-
targeted therapies (10). On a transcriptome level, the
networks of HIV-1-infected CD4 T cells have already been
studied both in vitro (5) and in vivo (11, 12). However, the
changes detectable on the transcriptome level are largely
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driven by viral replication. Therefore, they are not ideal for the
discovery of mechanisms of viral control (11). In contrast,
proteins are the main molecular effectors of the cell and are at
the functional interface between virus and host. Analysis of
the proteome may therefore be useful to detect new mecha-
nisms associated with control of the virus.
Mass spectrometry (MS) has increasingly become the
method of choice for analysis of complex protein samples,
both qualitatively and quantitatively (13). We have recently
developed SWATH-MS, a technique that combines the high
quantitative accuracy of targeted proteomics with the broader
coverage achievable with discovery proteomics. In essence,
SWATH-MS is a massively parallel targeted mass spectro-
metric strategy that requires the a priori generation of spectral
libraries that are then used to identify and quantify query
peptide in the acquired datasets (14, 15). SWATH-MS pro-
vides selected reaction monitoring-like performance in terms
of reproducibility, quantitative accuracy, data completeness,
and dynamic range (16). Furthermore, and unlike selected
reaction monitoring, SWATH-MS can quantify an unlimited
number of target peptides as long as they have been previ-
ously observed by DDA1 (15).
MS approaches have been used previously to quantify the
changes in the proteome of T cell lines and macrophages
upon infection with HIV-1 (7, 8). However, the proteome of the
main target cell of HIV-1, the human CD4 T cell, has not
been assessed yet.
In this study, we describe the results of the exploratory
study in which the proteome of human CD4 T cells, the most
important target cell for HIV-1, is quantified to detect the
changes associated with HIV-1 infection. By infecting human
CD4 T cells in vitro and following the effects of the infection
on the host proteome over time and by assessing the pro-
teome differences in paired samples from viremic and subse-
quently treated patients with no detectable viral load, we
aimed to cover the changes of the CD4 T cell proteome
associated with HIV-1 infection in both in vitro and in human
individuals. The data re-iterate the central role for type 1
interferon during HIV-1 infection and suggest a possibly novel
role for TLR-4 signaling. Finally, the changes in the proteome
during in vitro and the in vivo HIV infection are to large extent
dissimilar, except for significant enrichment of type 1 inter-
feron signaling upon functional enrichment analysis.
PATIENTS AND METHODS
Patients—10 HIV-1-infected individuals were enrolled from
the longitudinal Zurich Primary HIV-1 Infection Study (ZPHI),
which is an open label, non-randomized, observational, sin-
gle-center study (www.clinicaltrials.gov, ID 5 NCT00537966)
(17). Blood samples at two different time points of each pa-
tient were investigated. At time point 1, the patients were not
treated and had HIV-1 detectable. At time point 2, the patients
were treated and had no detectable viral load for a minimum
of 6 months. For patient details, see Table I.
Ethics Statement—The ethic committee of the University
Hospital Zurich approved the study protocol and a written
informed consent was obtained from all patients. Buffy coats
from healthy donors were received from the Blood Donation
Service Zurich, Swiss Red Cross, Switzerland. Written in-
1 The abbreviations used are: DDA, data-dependent acquisition;
ZPHI, Zurich Primary HIV-1 Infection Study; PBMC, peripheral blood
mononuclear cell; m.o.i., multiplicity of infection; ACN, acetonitrile;
FA, formic acid; TPP, tripeptidyl-peptidase.
TABLE I
Patient characteristics
Patient IDs Treatment Viral load, copies/ml CD4/mm3 % CD4 CD8/mm3 % CD8
1 off 81,800 486 20 1,155 48
on 20 517 17 1,505 49
2 off 144,000 391 24 809 51
on 20 359 26 644 47
3 off 32,500 440 20 1,371 61
on 20 477 40 463 39
4 off 2,370 478 36 611 46
on 20 503 41 478 39
5 off 996,000 420 35 546 46
on 20 793 56 294 21
6 off 38,300 376 24 842 54
on 20 668 29 1,075 47
7 off 29,000 476 31 709 46
on 20 667 35 638 34
8 off 3,510 462 30 616 40
on 20 582 24 739 31
9 off 110,000 614 31 1,097 56
on 20 692 36 911 47
10 off 27,100 602 34 826 47
on 20 758 46 551 33
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formed consent was obtained for the use of buffy coats for
science, which were not needed for medical purposes by the
Blood Donation Center.
CD4 T Cell Culture and Infection—Peripheral blood mono-
nuclear cells (PBMCs) were isolated from buffy coats, as
described previously (18), and enriched for CD4 T cells by
magnetic microbeads according to the manufacturer’s proto-
col (Miltenyi Biotec). After a three-way stimulation (phytohe-
magglutinin 5.0 g/ml, phytohemagglutinin 0.5 g/ml, and
Oct3) for 3 days, the cells were infected with HIV-1JR-FL by
spinoculation for 2 h at 1,200  g at a multiplicity of infection
(m.o.i.) of 1 (19). After infection, the cells were washed twice in
PBS and cultured in RPMI 1640 media containing penicillin/
streptomycin, 10% FCS, and 50 units of IL-2/ml. Supernatant
for p24 ELISA was collected 0, 12, 24, and 48 h post-infec-
tion. The time points were chosen to allow the virus to finish
a full infectious circle (5). CD4 T cell purity was confirmed by
flow cytometry, ranging between 96.3 and 99.8%. The HIV-
1JR-FL virus stock was generated by transfection of 293 T cells
with pJR-FL and titrated on PBMCs (18).
Cryopreserved PBMC Procedures—Cryopreserved PBMCs
were thawed in a 36 °C water bath and were washed twice
with PBS at room temperature. 1  106 cells were lysed
immediately, and the remaining cells were positively selected
using magnetically labeled CD4 and CD8 microbeads and
subsequent column purification according to the manufactu-
rer’s protocol (Miltenyi Biotec). CD4 T cell purity, verified by
flow cytometry, was 97.8% (96.3–99%) (median (range).
Experimental Design and Statistical Rationale—For the in
vitro infection experiment, each time point, including controls,
was performed in triplicate. Each sample represents a biolog-
ical replicate. For the MapDIA statistical model, three biolog-
ical replicates were sufficient. For the human samples, a total
of 10 patient’s samples were obtained. Two patients were
excluded due to low cell numbers. Therefore, a total of eight
patients were measured at each time point, representing a
biological replicate each. We were able to maintain the Rep-
licate Design Model, which enabled us to use the MapDIA
statistical model despite the exclusion of two samples.
Proteomics Sample Preparation—Approximately 1  106
cells were washed with PBS and resuspended in lysis buffer
containing 1.2% sodium deoxycholate monohydrate in 50 mM
ammonium bicarbonate buffer (150 l per 1  106 cells). The
cell suspension was thoroughly vortexed and incubated at
room temperature for 10 min while shaking at 1,000 rpm.
Subsequently, cells were subjected to three 10-min cycles of
sonication at 4 °C (100% output, 50% intervals, Branson
Sonifier 450, Emerson).
Ice-cold acetone (20 °C) was added to the lysate at a rate
of 6 volumes to 1 volume of lysate and incubated for 1 h on
ice. The cell lysate was centrifuged for 15 min at full speed at
4 °C, washed another three times with ice-cold acetone, and
then allowed to dry completely. The proteins were resus-
pended in 8 M urea, 100 mM ammonium bicarbonate buffer.
The protein concentration was estimated using the BCA as-
say (Pierce). From each sample only 50 g of protein was
used for subsequent steps. Protein disulfide bonds were re-
duced by adding 5 mM tris(2-carboxyethyl)phosphine and
incubating for 30 min at 30 °C. Free cysteine residues were
alkylated by adding 40 mM iodoacetamide and incubating for
60 min in the dark at room temperature. Subsequently, the
samples were diluted with 0.05 M ammonium bicarbonate
buffer to a urea concentration of 2 M, and 1 g of sequenc-
ing grade modified trypsin was added (w/w 1:50). The sam-
ples were incubated overnight at 30 °C with shaking at 300
rpm. To stop the tryptic digest, the pH was lowered to 2 using
trifluoroacetic acid (final concentration of 1%) followed by
an incubation for 30 min at 37 °C with shaking at 500 rpm.
The cleared peptide solution was desalted with C18 Micro-
Spin columns (The Nest Group, 5–60 g loading capacity).
Prior to use, the C18 columns were activated with 100%
methanol, followed by 80% acetonitrile (ACN), 0.1% TFA,
followed by equilibration with 2% ACN, 0.1% TFA. After load-
ing, the columns were washed with 2% ACN, 0.1% TFA.
Subsequently, the peptides were eluted with 40% ACN, 0.1%
TFA, dried under vacuum, resolubilized in 2% ACN, 0.1% FA,
and added at 1:20 with iRT peptides (Biognosys).
Spectral Library and SWATH Peptide Query Parameter
Generation—The spectral library and SWATH peptide query
parameters were generated essentially as described (20). The
TripleTOF 5600 mass spectrometer (AB Sciex) was coupled to
a nanoLC 1Dplus system (Eksigent), and the chromatographic
separation of the peptides was performed on a 20-cm emitter
(75 m inner diameter, New Objective) packed in-house with
C18 resin (Magic C18 AQ 3 m diameter, 200 Å pore size,
Michrom BioResources). A linear gradient from 2 to 35%
solvent B (solvent A, 2% ACN, 0.1% FA; solvent B, 98% ACN,
0.1% FA) was run over 120 min at a flow rate of 300 nl/min.
The mass spectrometer was operated in IDA mode with a
500-ms survey scan from which up to 20 ions exceeding 250
counts/s were isolated with a quadrupole resolution of 0.7 Da,
using an exclusion window of 20 s. Rolling collision energy
was used for fragmentation, and an MS2 spectrum was re-
corded after an accumulation time of 50 ms. Raw data files
(wiff) were centroided and converted into mzML format using
the AB Sciex converter (beta version 2011) and subsequently
converted into mzXML using openMS (version 1.8). The con-
verted data files were searched using the search engines
X!Tandem (k-score, version 2013.06.15.1) and Comet (version
2013.02, revision 2) against the UniProt-SwissProt complete
proteome for Homo sapiens (canonical sequences) with the
protein sequences derived from full-length consensus se-
quences of viral RNA genome of both the HIV-1JR-FL strain
used for the in vitro infection model and the viral RNA se-
quences of 8–10 patients (HIV_fasta_file.txt, supplemental
material) (21). The enzyme specificity was set to fully tryptic
with two missed cleavages allowed. In total, the database
contained 20,149 target sequences and 20,117 decoy se-
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quences. The tolerated mass errors were 50 ppm on MS1
level and 0.1 Da on MS2 level. Carbamidomethylation of
cysteines was defined as a fixed modification and methionine
oxidation as a variable modification. The search results were
processed with PeptideProphet and iProphet as part of the
TPP 4.7.0. The spectral library was constructed from the
iProphet results with an iProphet probability cutoff of 0.98422,
corresponding to a 1% FDR on a protein level as determined
by Mayu (version 1.08). The raw and consensus spectral
libraries were built with SpectraST (version 5.0) using the
-cICID_QTOF option for high resolution and high mass accu-
racy and -c_IRT and -c_IRR options to normalize all retention
times according to the iRT peptides with a linear regression.
The six most intense y and b fragment ions of charge state 1
and 2 were extracted from the consensus spectral library
using spectrast2tsv.py from msproteomicstools (https://pypi.
python.org/pypi/msproteomicstools). Fragment ions falling into
the swath window of the precursor were excluded as there is
often interference with the resulting signals. Decoy transition
groups were generated based on shuffled sequences (decoys
similar to targets were excluded) by the OpenMS tool Open-
SwathDecoyGenerator (version 1.10.0) and appended to the
final SWATH library in TraML format (20).
SWATH Data Acquisition—TripleTOF 5600 mass spectrom-
eter was set up as described above but operated in SWATH
mode using the following parameters. For liquid chromatog-
raphy, a linear gradient from 2 to 35% solvent B (98% ACN,
0.1% FA) was run over 120 min at a flow rate of 300 nl/min
(patient samples) or 5–30% over 60 min (in vitro infections).
Acquisition of a 250-ms survey scan was followed by acqui-
sition of 64 fragment ion spectra from 64 precursor isolation
windows (swaths) with variable width chosen to minimize
precursor ion density in each window (16). The swaths were
overlapping by 1 m/z and covered a range of 400–1200 m/z.
The SWATH MS2 spectra were recorded with an accumula-
tion time of 50 ms and cover 100–2000 m/z. The collision
energy for each window was determined according to the
calculation for a charge 2 ion centered upon the window
with a spread of 15. Raw data files (wiff) were converted into
mzXML format using ProteoWizard as described (14).
SWATH Data Analysis with OpenSWATH—The SWATH
data were analyzed using OpenSWATH version 1.10 with the
following parameters. Chromatograms were extracted with
0.05 m/z around the expected mass of the fragment ions and
with an extraction window of 5 min around the expected
retention time after iRT alignment. The best model to separate
true from false positives (per run) was determined by py-
prophet with 10 cross-validation runs. The runs were subse-
quently aligned using TRIC as described with a target FDR of
0.01 (22).
Relative Protein Quantification—To obtain fold changes and
corresponding p values of all proteins compared with the
time-matched uninfected controls for in vitro infections, or
non-viremic patient samples, the software MapDIA was used.
Median normalization was applied prior to analysis by Map-
DIA throughout. A model-based statistical significance anal-
ysis of protein level differential expression between the
groups of interest was performed as described in the MapDIA
package. iRT peptides and serum proteins (samples were
stored in BSA containing buffer) were removed from the anal-
ysis (supplemental Fig. 1).
Protein Abundance Estimation—For label-free abundance
estimations of all proteins identified by SWATH MS, the aLFQ
package was used (23). Protein abundances were computed
as the sum of the top five most intense fragment ions from the
three most intense peak groups. The TRIC strategy for auto-
mated peptide alignment was used (22). Requantified values
were used when no reliable signal was found. A protein had to
be detected for a minimum of three times per group in order
for the remaining values to be requantified and considered for
downstream analysis.
Clustering, Functional Annotation, and Network Analysis—
Clustering was performed using the heatmap2 function in R.
For functional annotation, the ClueGO app for Cytoscape was
used (24). An Enrichment/Depletion method with a two-sided
hypergeometric test was applied, correcting with a Bonferroni
step down correction. Min GO level was set to 4 and Max GO
level to 10. The protein list from the spectral library was used
as background throughout. For networks based on STRING,
an evidence grade cutoff of 0.4 was used.
RESULTS
Qualitative Characterization of the HIV-1 and Host Cell Pro-
teomes—CD4 T cells from blood donors were isolated and
infected in vitro with HIV-1JR-FL(18). The study approach is
summarized in Fig. 1A. The HIV-1 protein p24 was quantified
by ELISA in the supernatant to confirm successful infection
(Fig. 1B). Because human CD4 T cells need to be activated
for successful infection with HIV-1 in vitro, we focused our
analysis on the log2 fold changes between paired infected
and uninfected cells at a given time point. To generate
a spectral library for use as reference in generating pep-
tide query parameters for the peptide-centric analysis of
SWATH-MS data, we performed DDA analysis of the pro-
teomes of in vitro HIV-1-infected human CD4 T cells as well
as sorted CD4 T cells, CD8 T cells, and PBMC from HIV-
1-infected individuals (Fig. 1A and supplemental Fig. 2) fol-
lowing our published protocol (20). We added the sequence of
HIV-1JR-FL used for in vitro infection as well as eight full-length
HIV-1 sequences from patients to our protein sequence da-
tabase. This resulted in a reference spectral library (Fig. 1A,
qualitative MS), consisting of 3,360 proteins based on 22,901
peptides with an FDR of 1% on the protein level, including
four HIV-1 proteins: Env_gp120; Nef; matrix protein (p17); and
capsid protein (p24) (Table II, HIV_fasta_file.txt). Using DDA
mode for the library creation, we were able to detect HIV-1
proteins from in vitro experiments only, despite adding the
matching HIV-1 sequence of the individual virus of each pa-
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tient from 8 of the 10 patients. Overall, it is not very surprising
that we were unable to find viral proteins in human individuals,
given that even in actively replicating patients 1 of 617–771
of CD4 T cells is productively infected, i.e. produces viral
protein (25). In contrast, after spinoculation with an m.o.i. of 1,
close to 100% of CD4 T cells are infected in vitro.
Changes in the Proteome of in Vitro HIV-1-infected CD4 T
Cells over Time—To determine the changes of the proteome
associated with HIV-1 infection, we measured quantitative
proteome profiles of CD4 T cells infected in vitro with HIV-1
by SWATH-MS. Of 1,725 proteins (1% FDR) consistently
quantified during the time course, a total of 145 unique pro-
teins (8%) were significantly different between infected and
uninfected CD4 T cells according to a differential protein
expression analysis using a Bayesian hierarchical model as
implemented in mapDIA (26), using a threshold of (FDR0.05
and log2 fold changes 1 and  1) (supplemental Table 1).
The most profound changes in the proteome were detectable
24 h after infection (Fig. 2A). To assess the overall structure of
the changes in the proteome, we performed hierarchical clus-
FIG. 1. Experimental design. A, lysates from human CD4 T cells as well as PBMC, sorted CD4 T cells, and sorted CD8 T cells were used
to generate a spectral library and HIV-1 sequences (qualitative MS). Using this library, both relative changes between the samples of interest
as well as protein abundance (quantitative MS) were calculated using the mapDIA and the aLFQ package, respectively. B, p24 in the cell culture
supernatant from infected CD4 T cells as detected by ELISA.
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tering of differentially expressed proteins. We were able to
detect four high level clusters over the time course. Compared
with uninfected CD4 T cells, clusters of down-regulated
proteins were most prominent. To illustrate the dynamics of
the four clusters, we plotted all the traces of each cluster and,
additionally, selected proteins from each cluster (Fig. 3). To
assess the changes in the proteome and the structure of the
clusters on a functional level, we applied Gene Ontology (GO)
term enrichment analysis to the different clusters (24). The
blue cluster a (Fig. 2B) contains 30 proteins and displayed a
biphasic trace with up-regulation at time point of 24 h and
down-regulation at time point of 48 h (Fig. 3A).
Cluster a in blue (Fig. 3A) contained TPP-1. Functional
enrichment analysis showed significant enrichment of ser-
ine endopeptidase activity, cysteine endopeptidase activity,
and symporter and phosphatase activity (Fig. 4A and
supplemental Table 2).
Cluster b in turquoise consists of 25 proteins (Fig. 2B),
which are down-regulated over the course of infection (Fig.
3B). There was no enrichment of GO terms detectable for this
cluster. Cluster b contains the protein phosphatase 3 catalytic
subunit  (PPP3CA), a calmodulin-stimulated protein phos-
phatase (Fig. 3B).
Cluster c contains 27 proteins, and they are marked in olive
green (Fig. 2B). The overall trace displays an early down-
regulation of proteins after 12 h after infection (Fig. 3C). GO
term enrichment analysis revealed one significantly enriched
functional term, transcription corepressor activity. Cluster c
contains TRNA methyltransferase 11–2 (TRMT 112), which is
involved in the methylation of tRNA and proteins (Fig. 2C).
Cluster d in red (Fig. 2B) is the largest cluster with a total of
63 proteins (Fig. 2B). The general trace displays down-regu-
lation of proteins after 24 h (Fig. 3D). The single protein shows
protein S100-A8, which belongs to the group myeloid-related
proteins After a three-way stimulation (phytohemagglutinin
5.0 g/ml, phytohemagglutinin 0.5 g/ml, and Oct3) for 3
days, (Fig. 3D). Functional enrichment analysis showed sig-
nificant enrichment of multiple GO terms, including TLR-4
binding, type 1 interferon signaling pathways, nucleosome
binding, endopeptidase inhibitor activity, and ribonucleotide
diphosphatase reductase activity (Fig. 4B and supplemental
Table 2). In sum, we can re-capitulate the dynamics of single
proteins known to be important during HIV infection in the
context of the changing proteome.
We attempted to correlate our differential proteome data
with gene expression data from a previous study (5); however,
no significant correlation of the log2 fold change versus un-
infected controls for transcripts and protein could be found
(supplemental Fig. 3). Although the infection experiment in
this paper was similar, there were significant differences, par-
ticularly with respect to the host cell line used (T cell line in the
cited transcript study as opposed to primary CD4 T cells in
our experiment). The lack of correlation may also reflect the
complex dynamics of the infection system and the temporal
difference in protein and transcript responses, but to address
this, a study designed specifically to address this would be
required.
Abundance and Dynamics of Viral Proteins—In this section,
we aimed to measure HIV proteins within the host proteome.
For the quantification of viral proteins, the protein abundances
were determined by best flyer peptide approach (27) using the
aLFQ package (23). In in vitro HIV-1-infected CD4 T cells, the
production of the intracellular viral protein peaked at 24 h
with a swift decrease at 48 h (Fig. 4A). The most prominent
changes in the human proteome occurred simultaneously,
peaking at time point 24 h (Fig. 1A). All four HIV-1 proteins
measured displayed highly synchronous dynamics. To depict
the abundance of viral proteins in the context of the host
proteome, we plotted those abundances in the context of
the host proteins at 24 h and highlighted host proteins
associated with the GO group “viral defense” (Fig. 4B).
Within 24 h, absolute viral protein quantities match consti-
tutively expressed proteins like CD4.
It is noteworthy that the proteins detected after 24 h are all
structural proteins except for NEF. This is in line with the
observation that HIV-1 completes the viral cycle at this time
point (5). Therefore, it is not surprising to detect proteins that
are consistent with an intact virus, like p17, a matrix protein
with immune modulatory capacity. NEF remained highly ex-
pressed at this time point, in absolute quantities close to the
amount of CD4. The inhibitory activity of NEF on CD4 is well
established (28). Hence, these data suggest that the immune
modulatory protein NEF remains to be expressed at high
levels despite the successful production of late viral proteins.
Indeed, NEF induces a massive secretory state not only in
HIV-1-infected cells but also bystander cells (29). Therefore, it
is suggestive that the massive production of NEF together
with intact virus at time point 24 h is likely to facilitate subse-
quent infections.
Changes in the Proteome of CD4 T Cells from Patients Are
Associated with HIV-1 Viremia—Next, we tried to determine
whether any of the changes observed in the in vitro HIV-1
TABLE II
HIV proteins
Viral protein Function Seq. coverage (%) distinct peptides
Env_gp120 Part of gp160, binds to CXCR4/CCR5 7.4 3
Nef Early protein, inhibits T cell activation 11.1 2
P17 Part of GAG, structural protein 36.9 13
P24 Capsid, forms conical core of virions 18.0 4
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infection model are recapitulated in CD4 T cells from HIV-
1-infected individuals. Samples were collected from patients
participating in the longitudinal Zurich Primary HIV-1 Infection
Study. Samples were obtained from patients during viremia as
well as at least 6 months after successful antiretroviral treat-
ment where no viral load was detectable (Table I). Therefore,
we cannot exclude that the medication itself contributes to
the observed changes of the proteome. The clinical samples
were heterogeneous in terms of absolute protein yield ex-
tracted due to low cell numbers after sorting. Samples with
too low amounts of cells were excluded pairwise to retain the
Replicate Design Model. We were unable to link to any spe-
cific pattern, such as prolonged storage, probably due to the
limited sample number. In total, we were able to measure the
proteome in two time points each from CD4 T cells of eight
individual patients, and we were able to consistently measure
895 proteins in CD4 T cells. Next, we compared the quan-
titative changes in CD4 T cells in patients during HIV-1
viremia and after successful therapy. Overall, the changes
were not very pronounced in terms of log2 fold changes (Fig.
5A). Because CD4 T cells are the main population of infected
cells in peripheral blood, it is to be expected that this cell
population shows the biggest changes upon treatment. Using
an FDR cutoff of 1% and log2 fold changes of 0.5 to 0.5,
as threshold for significance, 57 proteins were up-regulated,
and 115 were down-regulated in CD4 T cells. After func-
tional enrichment analysis, the GO terms RNA polymerase II
core promoter, type 1 interferon signaling, neutrophil killing of
a symbiont cell, and antigen presentation were enriched in
up-regulated proteins (Fig. 5B and supplemental Table 2).
Specifically, the small ubiquitin-like protein-modified interfer-
on-stimulated gene 15 (ISG)-15 plays an important role by
inhibiting the release of HIV-1 particles (30), and correlates
with viral load in humans (31). The rather unexpected finding
of increased syntaxin-binding protein (STXBP)-2 is in line with
findings in a Jurkat T cell line, showing that STXBP-2 is a
strong inhibitor of retroviral transcription (32). RuvB-like 2
(RVB2), an ATP-dependent DNA helicase, is exploited by
HIV-1 to retain the correct ratio of the HIV-1-1 structural
protein Gag to the envelope protein Env; in addition, RVB2
levels correlate with HIV load in humans (33). The detection of
the proteins TAP-1 and TAP-2 suggests that there is a con-
tamination of CD4 T cells with dendritic cells. Dendritic cells
FIG. 2. Changes in the proteome of in vitro HIV-1-infected CD4
T cells over time. A, violin plots of log2 fold changes of proteins at
given time points comparing HIV-1-infected versus -uninfected CD4
T cells. Single proteins are connected by lines. Box plots show
mean  S.E. An FDR 0.05 and log2 fold changes 1 and 1 after
adjusting for multiple testing were considered significant. The model-
based statistical significance analysis from the mapDIA package was
used for statistical analysis. B, heat map displaying log2 fold changes
of proteins changing at least once significantly (FDR 0.05 and log2
fold changes 1 and 1) during the time course. Four high level
clusters are highlighted in blue (a), green (b), olive (c), and red (d),
respectively.
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FIG. 3. Traces and representative single proteins of clusters. Log2 fold changes of all traces of each cluster and a representative single
protein from each cluster are plotted in matching colors to the cluster they represent. Each letter (A–D) represents one of the clusters from Fig.
2. The violin plots represent the distribution of log2 fold change of every protein within the cluster. In the single protein figures, the black dots
represent single measurements; the colored dots represent the mean of the log2 fold changes.
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are producer of TAP-1 and TAP-2 and are known to express
CD4 when isolated from blood from human individuals (34).
Hence, a negative sorting approach may be more suitable for
this type of analysis. Among the down-regulated proteins, no
significant enrichment of GO terms was detectable.
Comparison of in Vitro Infected CD4 T Cells and CD4 T
Cells Sorted from Patients—Next, we aimed to compare in
vitro infected CD4 T cells and CD4 T cells from patients. In
a first step, we compared how the detected proteome of the
two cell populations overlaps (Fig. 7A). 829 proteins were
detected both in vivo and in vitro. Then, we compared all
proteins considered to be significantly differentially regulated
in both groups (Fig. 7B). The overlap was low with only 11
proteins changing both in vivo and in vitro. To assess whether
this lack of overlap was due to the fact that the main changes
were in proteins that were only detected in one of the groups,
we compared all the proteins considered different in the two
groups with the total of proteins detected in both groups
(overlap, Fig. 7C). In the in vitro experiment, 97 proteins were
considered different, which were not detected in the in vivo
samples, whereas 37 proteins considered to be regulated in
the in vitro time course were detected and considered as
FIG. 4. Functional annotation of the cluster analysis. A and B, network of significantly enriched functional annotation terms of down-
regulated proteins from cluster a (48 h after infection) and cluster b (24 h after infection), respectively. The GO terms immune system process
(diamond) and molecular function (ellipse) were assessed using the GO term fusion function from the ClueGO Cytoscape plugin. Different colors
were used for different functional groups. After network analysis of functional terms, the proteins underlying the significantly enriched functional
term were added (protein names are in red). The protein library was used as reference data set. Significance was assessed using a two-sided
hypergeometric test with a Bonferroni step down procedure to adjust for multiple testing.
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unchanged in the in vivo samples. Conversely, in the in vivo
samples 14 proteins were considered different, which were
not detected in the in vitro samples, whereas 147 proteins
which were differentially regulated in the in vivo samples
were detected and did not change in the in vitro time
course. Hence, of the proteins that were detected in both
sample types some overlap in differential expression was
observed; however, the majority of proteins that were dif-
ferentially expressed in vitro did not change in vivo and vice
versa.
Functional enrichment analysis showed significant enrich-
ment of type 1 interferon signaling in both in vitro infected
CD4 T cells as well as CD4 T cells from patients. 4 and 5
proteins in vitro and in vivo, respectively, were significantly
enriched for the GO term “type 1 interferon signaling” (Figs.
4B and 6C). A network based on published interactions using
evidence based only on experiments and databases from
STRING confirmed that the proteins are interacting based on
experimentally observed protein-protein interactions (Fig. 7D).
However, the type 1 interferon pathway is a central pathway in
innate and adaptive immunity. Furthermore, type 1 interferon
signaling may have both protective or detrimental effects for
the host, depending on the timing, the state of the cell, and
the cellular milieu (35). Consequently, assessing functionality
based on the broad GO term “type 1 interferon signaling”
might be an oversimplification. Therefore, we plotted the sig-
FIG. 5. Analysis of detected HIV-1 proteins. A, estimated abundances of HIV-1 proteins in CD4 T cells over time as assessed by aLFQ.
B, dynamic range of HIV-1 protein quantification within the whole proteome of CD4 T cells after 24 h. The log10 abundance of all proteins
detected is plotted. HIV-1 proteins are highlighted in red, human proteins of the functional GO term viral defense are highlighted in blue.
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nificantly enriched proteins within a diagram of interferon /
signaling obtained from the REACTOME database (Fig. 8, A
and B) (36). In direct comparison, differentially regulated pro-
teins in vivo affect primarily proteins activating STAT-1, in-
cluding STAT-1 itself; in turn, differentially regulated proteins
in vitro are located downstream of STAT-1 activation in the
FIG. 6. Qualitative and quantitative assessment of the proteome of human CD4 T cells. A, volcano plot showing log2 fold change of
protein abundance plotted againstlog10 adjusted p value for CD4 T cells from viremic patients versus the same viremic patient. Data points
highlighted in blue in the upper right section represent proteins that display an enrichment in of log2 fold change 0.5 and adjusted p value
0.05. A total of seven patients was assessed for this comparison. B, network of significantly enriched functional annotation terms of proteins
from up-regulated proteins comparing the same patient during viremia and after successful treatment. The GO terms “immune system
process” (diamond) and “molecular function” (large circle) were assessed using the GO term “fusion function” from the ClueGO package.
Different colors were used for different functional groups. After network analysis of functional terms, the proteins underlying the significantly
enriched functional term were added (small circle, protein names are in red). The protein list from the spectral library was used as reference data
set. Significance was assessed using a two-sided hypergeometric test with a Bonferroni step down procedure to adjust for multiple testing.
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pathway, such as mediators of an antiviral state like IRF-4.
Hence, despite the significant enrichment of the GO term type
1 interferon signaling in vivo and in vitro, the actual proteins
may be different as well as their biological function (35). In
sum, there is little overlap between the specific changes in the
proteome comparing in vivo and in vitro infected CD4 T cells
but rather convergence at the pathway level of type 1 inter-
feron signaling.
DISCUSSION
We examined the changes in the proteome of human CD4
T cells associated with HIV-1 infection both in vitro and in vivo.
The most profound changes in the overall proteome of CD4
T cells infected with HIV-1 in vitro were detected 24 h after
infection and involved important functional groups within the
cell. In addition, we could measure the abundance and dy-
namics of certain HIV-1 proteins within the host proteome.
Finally, we could reiterate some of the findings from the
in vitro model using CD4 T cells from HIV-1-infected
individuals.
The proteome of in vitro HIV-1-infected human T cells has
not been measured yet. Here, we present data from a com-
prehensive set of samples with longitudinal in vitro and in vivo
samples. In addition, we could detect viral proteins, which
FIG. 7. Comparison of the proteome of CD4 T cells from the in vitro infection and from patients. A, Venn diagram of all proteins
detected in sorted CD4 T cells in the in vitro infection experiment and CD4 T cells from patients. B, Venn diagram of all significantly regulated
proteins detected in sorted CD4 T cells in the in vitro infection experiment and CD4 T cells from patients. C, Venn diagram comparing the
proteins found in both the in vitro and the in vivo experiments with the proteins that were regarded as significantly regulated in the in vitro
infection experiment and in CD4 T cells from patients. D, significantly enriched proteins from the network analysis in Figs. 4 and 6 plotted as
STRING network using a confidence cutoff of 0.4, including interactions obtained from experiments and curated databases only. Nodes
connected by red edges represent proteins from the in vitro experiment; nodes connected by green edges represent proteins from the in vivo
experiment.
Proteome Analysis of HIV-1 Infected, Human CD4 T Cells
Molecular & Cellular Proteomics 16 Supplement 4 S119
enables us to put them in the context of the host proteome. A
strength of our approach is the paired approach for both in
vitro and in vivo samples. By comparing cells from the same
donor or the same individuals at different time points, we can
reduce inter-individual differences.
During the in vitro infection time course, changes in the
CD4 T cell proteome were most prominent 24 h after infec-
tion, simultaneous with the peak of viral protein production.
GO term enrichment of immune system processes showed a
decrease of proteins associated with TLR-4 signaling and
type 1 interferon signaling. TLR-4 signaling has been shown
to be an important regulator of T cell receptor signaling in T
cells from mice (37). Conversely, the HIV-1 envelope protein
gp120 has been shown to bind to TLR-4 (38). Our investi-
gation shows a strong time-dependent association of de-
creased TLR-4 signaling and increased gp120 in the in vitro
experiment.
Type 1 interferon signaling plays a central role in viral in-
fections and has pleiotropic effects. Depending on the bio-
logical context, type 1 interferons may promote or inhibit T cell
FIG. 8. REACTOME diagrams of the type 1 interferon signaling pathway with highlighted and regulated proteins from the in vivo and
in vitro experiments. A, REACTOME diagram of the type 1 interferon signaling pathway highlighted (in purple), with differentially regulated
proteins in CD4 T cells from patients on and off treatment. B, REACTOME diagram of the type 1 interferon signaling pathway with highlighted
(in purple) and differentially regulated proteins in CD4 T cells infected in vitro at the 24-h time point.
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activation, proliferation, differentiation, and survival (35). This
central role may explain that we could detect changes in pro-
teins associated with type 1 interferons both in vitro and in vivo.
Our enrichment analysis used the protein library only.
Therefore, the number of proteins being enriched appears on
first sight to be rather low. However, because the number of
proteins in our custom protein library for a given GO term is
limited, the enrichment is significant even with a low total
amount of proteins. For example, four proteins linked to the
GO term type 1 interferon changed in the in vitro experiment.
The total number of proteins in our library linked to type 1
interferon is 31. Therefore, four changing proteins accounts
for13% of all type 1 interferon-associated proteins, which is
significant.
Our proteome approach and the re-discovery of certain
proteins in the context of the whole proteome may be used to
support results from genome analyses and put them into
biological context. A recent meta-analysis of host cell genes
involved in HIV-1 infection emphasized the importance of
networks around STAT-1 (39), in line with our in vivo results.
Hence, our proteome approach introduces not only an addi-
tional level of evidence on the proteome level in vitro but also
re-emphasizes and highlights the role of these proteins in
actual human individuals.
In addition to host proteins, we could directly detect HIV
proteins in the in vitro time course. To the best of our knowl-
edge, we are the first ones to report HIV proteins within the
human proteome outside of protein-protein interactions stud-
ies (40). We could detect the most abundant late proteins at
time point 24 h. The 12-h time may have been too early for the
early HIV proteins, such as Tat and Rev (6). The other viral
proteins might be expressed at insufficient levels for detection
using our single-shot analysis method. This obstacle could be
overcome by infecting a more susceptible T cell line that is
known to produce much more HIV-1 proteins (5). However, in
this study, we focused deliberately on primary CD4 T cells
and clinical samples to assess the translational potential of
SWATH-MS. CD4 T cells produced a significant amount of
HIV-1 proteins within 24 h. In this experimental setting, we
measure the overall protein production within the CD4 T cell
population, which consists of infected and uninfected T cells.
Therefore, from a single cell perspective, the total amount of
HIV-1 protein produced is likely to be diluted and very likely to
be higher than our estimate, although we tried to minimize the
number of uninfected cells by using a multiplicity of infection
of 1 in combination with spinoculation to synchronize the
infection and enhance the infection rate, i.e. theoretically,
each cell should be infected by HIV-1. However, not every
primary CD4 T cell is, even after maximal stimulation, sus-
ceptible for HIV-1 infection in vitro (41).
Our results differ to some extent from previous data pub-
lished on the proteome of in vitro infected T cell lines (7, 42).
The study of Chan et al. found changes in 21% of proteins
upon HIV infection. However, because T cell lines used are
hyper-susceptible for HIV infection compared with human
samples, direct comparison to our results is difficult.
Next, we assessed paired CD4 T cells from patients on
and off treatment. Nevertheless, the differences in CD4 T
cells were most pronounced between viremic and non-vire-
mic patients. Whether this is a sampling bias or a real biolog-
ical phenomenon remains unclear. However, it is tempting to
speculate that as CD4 T cells are the main reservoir of HIV-1
in peripheral blood, they are most prone to changes upon
treatment. The number of proteins detected from the clinical
samples was low compared with cell lines but was compara-
ble with other clinical tissues (43) and similar to a previous
study that analyzed PBMCs by SWATH-MS (44). As such,
optimization of the sample preparation from patient-derived
PBMCs, combined with a deeper coverage in the spectral
library via fractionation, may yield improved proteome cover-
age in future studies. A further limitation of the in vivo com-
ponent of our study was the relatively limited numbers of
patient samples analyzed, which resulted in a relatively low
number of proteins called as differentially expressed likely
reflecting the large differences in genetic and environmental
backgrounds of the patients. Hence, because of the hetero-
geneity of data, the patient samples represent a pilot analysis,
and a larger number of samples is required for more statistical
power to overcome strongly confounding signals not related
to the viral infection.
Even though we used primary human CD4 T cells for the
in vitro infection, it is difficult to compare these findings di-
rectly to the changes detected in the proteome of patients
during HIV-1 infection. First and foremost, the relationship of
infected versus bystander cells is fundamentally different. In
vitro, we expect a high percentage of infected cells, whereas
in vivo the overwhelming majority of cells is not infected (41).
In addition, for an in vitro infection of human CD4 T cells to
be successful, the cells must be artificially activated. Hence,
the in vitro data in our investigation display the changes within
the proteome against a strong background of activation. We
tried to be as specific as possible to detect only changes
associated with HIV-1 by comparing activated and simulta-
neously HIV-1-infected cells against activated cells only at the
same time points. This approach notwithstanding, the detect-
able changes are still against a background of high activation.
In humans, in contrast, inflammation is associated with vire-
mia; suppression of viremia, in turn, abrogates inflammation.
Hence, the reported comparison of T cells from viremic versus
non-viremic patients includes changes attributable to resolv-
ing inflammation as well. Furthermore, the changes detecta-
ble over time in the in vitro system with a defined infection
time point are likely to occur at the same time in an infected
individual, for example, infection, integration, and assembly of
the virus are likely to happen constantly in humans and suc-
cessively in vitro. Finally, differences in the host (such as
genetic differences, differences within the virus, and differ-
ences in the handling of clinical samples) contribute to
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increase the noise within the measurements. Despite all
these drawbacks, we could link changes in the proteome
both in vivo and in vitro, for example with proteins associ-
ated with type 1 interferon signaling. However, it is worth
noting that there may be relevant biological differences in
the differentially expressed proteins associated with the GO
term “type 1 interferon signaling” in the in vivo and the in
vitro samples.
In sum, we analyzed the changes of the proteome of human
CD4 T cells associated with HIV-1 infection in both an in vitro
model of infection and cells derived from HIV-1-infected pa-
tients. To our best knowledge, the proteome of CD4 T cells
from HIV-infected humans has not been measured before.
Our results warrant further studies with larger patient numbers
and different clinical end points to better understand the host
immune system in HIV-1 infection.
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